HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 12, Pages 3514
Publisher
MDPI AG
Online
2020-11-27
DOI
10.3390/cancers12123514
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
- (2020) E. Antonio Chiocca et al. Molecular Therapy-Methods & Clinical Development
- Design of an interferon-resistant oncolytic HSV-1 incorporating redundant safety modalities for improved tolerability
- (2020) Edward M. Kennedy et al. Molecular Therapy-Oncolytics
- First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial
- (2019) Keri A. Streby et al. MOLECULAR THERAPY
- Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1
- (2019) Suzanne Thomas et al. Journal for ImmunoTherapy of Cancer
- ATIM-14. RESULTS OF PHASE II CLINICAL TRIAL OF ONCOLYTIC HERPES VIRUS G47Δ IN PATIENTS WITH GLIOBLASTOMA
- (2019) Tomoki Todo NEURO-ONCOLOGY
- A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
- (2018) Yoshiki Hirooka et al. BMC CANCER
- Oncolytic herpes simplex virus and immunotherapy
- (2018) Wenqing Ma et al. BMC IMMUNOLOGY
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3/4 Medulloblastomas and Atypical Teratoid/Rhabdoid Tumors
- (2017) Adam W. Studebaker et al. Molecular Therapy-Oncolytics
- Oncolytic Viruses in Cancer Treatment
- (2017) Sean E. Lawler et al. JAMA Oncology
- Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
- (2017) Ibrahim Ragab Eissa et al. Frontiers in Oncology
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma
- (2016) Lee A. Wheeler et al. NEURO-ONCOLOGY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
- (2016) Daxa M. Patel et al. Human Gene Therapy Clinical Development
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
- (2014) James M Markert et al. MOLECULAR THERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oncolytic herpes simplex virus vector G47Δ effectively targets breast cancer stem cells
- (2012) WEIGEN ZENG et al. ONCOLOGY REPORTS
- Sequence and comparative analysis of the genome of HSV-1 strain McKrae
- (2012) G. Watson et al. VIROLOGY
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
- (2010) A Nakao et al. CANCER GENE THERAPY
- Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
- (2010) Sunil K. Geevarghese et al. HUMAN GENE THERAPY
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy
- (2008) Kaitlyn J Kelly et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide
- (2008) Mark A Currier et al. MOLECULAR THERAPY
- A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer
- (2008) Yuman Fong et al. MOLECULAR THERAPY
- Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM
- (2008) James M Markert et al. MOLECULAR THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started